Sonoma pharmaceuticals reports first fiscal quarter 2025 financial results

European revenues increased 20% compared to same period last year gross margin of 39% compared to 35% in same period last year net loss improved 19% compared to same period last year boulder, co / accesswire / august 8, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology-based stabilized hypochlorous acid (hocl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended june 30, 2024. "this year marks the twentieth anniversary of the introduction of sonoma wound care products into europe; it is remarkable how our business has expanded and diversified in that time," remarked amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking